A new trial of a minimally invasive treatment for severe degenerative mitral regurgitation
Degenerative mitral regurgitation is a condition in which the valve’s two flap-like leaflets and supporting string-like structures (chords) are too stretchy and may even break.
When the heart contracts, the valve’s leaflets may not close correctly. This causes regurgitation, which occurs when blood leaks backward into the left atrium with each heartbeat.
Symptoms
However, some patients may not experience any symptoms at all.
Post-procedure doctor's visits and additional testing
Talk to your doctor or the clinical trial coordinator about the full list of eligibility criteria.
Continue the conversation with your cardiologist to determine if the RESTORE trial is right for you or find a heart surgeon participating in the trial below.
Hoag Memorial Hospital Presbyterian
Stanford University Medical Center
London Health Sciences Centre, University Hospital
St. Vincent Hospital of Indiana
University of Maryland Medical Center
Massachusetts General Hospital
University of Michigan Health System
Rutgers Robert Wood Johnson Medical School
Duke University Medical Center
Hospital of the University of Pennsylvania
UPMC/Pinnacle Health Hospitals
Caution: Investigational device. Limited by Federal (United States) law to investigational use. The device is not available for marketing or commercial sale in the United States. Edwards Lifesciences is the sponsor of the RESTORE trial.
Edwards, Edwards Lifesciences, the stylized E logo and HARPOON are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are property of their respective owners.
© 2022 Edwards Lifesciences Corporation. All rights reserved. PP–US-5113 v1.0
Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com